July 14, 2022

MultiplexDX released the newest version of its PCR test called SuperRapid

rTEST COVID-19 qPCR SuperRapid kit is an innovative, improved, and re-designed version of the WHO-recommended Charitè, Berlin protocol. The kit contains three sets of primers and hydrolysis probes (TaqMan®) for multiplex detection ofSARS-CoV-2 specific E gene and RdRP gene, together with human RNase P.

The SuperRapid kit provides the highest level of PCR testing concept. It is not just an environmentally friendly option (transportation and storage at room temperature; no dry ice and thermal boxes used), but users can have significant time & costs (very short sample processing & amplification time).

The test provides results in less than 45 minutes. This makes it a reliable fast solution for any testing needs, from big events, and airports, to local COVID-19 hotspots. The tests take samples through gargling instead of a nasal swab, which is uncomfortable for many. 

Main Features:

  • 1-Step RT-qPCR method 
  • No RNA extraction is necessary
  • Fast results: Reaction time reduced to < 45 minutes
  • At least 2 weeks of room temperature stability
  • Improved sensitivity of proprietary RdRP and E assays together     with RNase P assay as an internal control
  • SARS-CoV-2 full genomic RNA spiked with human RNA used as a     positive control
  • 100% clinical accuracy
  • 100% specific for SARS-CoV-2
  • Validated on real clinical samples
  • No cold chain shipping is needed

For more information or delivery terms, contact us at orders@multiplexdx.com. Samples are available upon request.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News